JPWO2018056284A1 - Composition for improving intestinal flora - Google Patents

Abstract

An object of the present invention is to provide a novel composition and an agent for promoting the production of the genus Ficalibacterium and a method for promoting the production of the genus Ficalibacterium. According to the present invention, there are provided a composition for promoting the production of Ficaribacillus bacteria comprising a cocoa-derived luminacoid and a production promoter of the Ficabacillus bacteria. According to the present invention, there is also provided a method for promoting the production of a genus of Ficalibacterium, which comprises ingesting an effective amount of cocoa-derived luminacoid.

Description

Reference to related applications

  This application claims the benefit of the priority of prior Japanese Patent Application No. 2016-184906 (filing date: September 21, 2016), the entire disclosure of which is incorporated herein by reference. Be part of

  The present invention relates to a composition for promoting intestinal flora improvement, and in particular to a composition for promoting the production of a ficalibacterium comprising a cocoa-derived luminacoid.

  The genus Ficacalibacterium (Faecalibacterium) belongs to the Clostridium cluster (Clostridium cluster IV, C. leptum subgroup) and is also detected in humans and non-human mammals (pig, mouse, calf, etc.) and poultry. Ficalibacterium is a short-chain fatty acid-producing bacterium (mainly producing butyric acid as a primary metabolite) that adheres to the mucus layer mainly secreted on the colonic epithelial mucosa (non-patent document 1). In addition, since the Ficalibacterium bacteria show the ability to induce regulatory T cells (Treg), anti-inflammatory and anti-allergic actions have been found (Non-patent Document 2). Furthermore, a disease in which the occupancy rate in the human intestinal flora is as high as several%, and the decrease in the fish bacteria is considered to be caused by dysfungal symbiotic balance (Dysbiosis). It is suggested that it may be associated with (such as Crohn's disease) (Non-patent Document 3).

  Cocoa beans store proteins and lipids as an amino acid source and energy source necessary for germination, and contain abundant dietary fiber as a structural material of cell walls. These are also contained in cacao mass which is a confectionery material prepared from cacao beans. It has been well known that dietary fibers such as polysaccharides and lignin show functionalities such as intestinal regulation and cholesterol excretion, but some proteins (resistant proteins) resistant to protease have recently been constipated. It has been clarified that it exhibits physiological functions similar to dietary fiber, indigestible dextrin and the like, such as the remission of (non-patent document 4). However, detailed knowledge on luminacoids derived from cocoa beans has not been obtained. On the other hand, it has been reported that the amount of feces increased when a mouse was fed with a protein fraction prepared by alkaline extraction and acid precipitation from cocoa beans (Patent Document 1).

International Publication No. 2012/133792

Int J Syst Evol Microbiol. 2002, 52 (6): 2141-2146 Curr Opin Microbiol. 2013, 16 (3): 255-261 Proc Natl Acad Sci USA 2008, 105 (43): 16731-16736 J Nutr Sci Vitaminol. 2002, 48 (1): 1-5

  An object of the present invention is to provide a novel composition for promoting the production of the genus Ficalibacterium and an agent for promoting the production of the genus Ficalibacterium.

  The present inventors have now found that a fat and oil processing composition containing a high concentration of cacao bean-derived luminacoid significantly increases the occupancy rate (%) of Ficalibacterium in human intestinal flora. I found it. The present invention is based on this finding.

According to the present invention, the following inventions are provided.
[1] A composition for promoting the production of Ficaribacterium comprising the cocoa-derived luminacoid (hereinafter sometimes referred to as “the composition of the present invention”) and the production acceleration of the Ficaribacterium Agent (hereinafter sometimes referred to as “agent of the present invention”).
[1-1] The composition for promoting the production of Ficaribacillus bacteria according to the above [1], wherein the cocoa-derived luminacoid is a cocoa bean-derived luminacoid, and the production accelerator of the Ficaribacterium genus [1- [2] The composition for promoting the production of a ficalibacterium according to the above [1] or [1-1], which comprises 0.5 g or more of a cocoa-derived luminacoid Production promoter.
[2] The food according to the above [1], [1-1] or [1-2], which comprises a daily amount of cocoa-derived luminacoid effective for promoting the production of the genus Ficaribacterium. A composition for promoting the production of a bacterium of the genus Calibacterium and a promoter for the production of a bacterium of the genus Ficalibacterium.
[3] The composition for promoting the production of Ficaribacterium according to the above-mentioned [2] and the production promoter of the genus Ficaribacterium, which are packaged per effective intake for one day.
[4] The fee according to the above [2] or [3], wherein the daily intake effective for promoting the production of the ficalibacterium bacteria is 0.5 to 11.9 g [the amount of cacao-derived luminacoid]. A composition for promoting the production of a bacterium of the genus Calibacterium and a promoter for the production of a bacterium of the genus Ficalibacterium.
[5] The food according to any one of the above [1], [1-1], [1-2] and [2] to [4], characterized in that the cocoa-derived luminacoid is ingested for 2 weeks or more. A composition for promoting the production of a bacterium belonging to the genus Bacillus and a promoter for promoting the production of a bacterium belonging to the genus Ficakaribacterium.
[5-1] The cocoa-derived luminacoid is ingested for 1 week or more at 0.5 to 11.9 g per day, characterized in that the above [1], [1-1], [1-2] and [2] The composition for promoting the production of the genus Ficaribacterium according to any one of [1] to [5] and the agent for promoting the production of the genus Ficaribacterium.
[6] The crispy according to any one of the above [1], [1-1], [1-2], [2] to [5] and [5-1], which is in the form of a fat and oil processing composition A composition for promoting the production of a bacterium belonging to the genus Bacillus and a promoter for promoting the production of a bacterium belonging to the genus Ficakaribacterium.
[7] The above-mentioned [1], [1-1], [1-2], for use in the treatment, prevention or amelioration of a disease or condition which can be treated, prevented or ameliorated by the production of a ficalibacterium genus bacteria. The composition in any one of [2]-[5], [5-1], and [6].
[8] A method for promoting the production of the genus Ficalibacterium, which comprises ingesting an effective amount of cacao-derived luminacoid.
[9] A Ficaribacterium genus bacteria according to the above-mentioned [8], which comprises ingesting a cocoa-derived luminacoid at a daily dose effective for promoting the production of the Ficaribacillus bacteria for one week or more How to promote the production of
[10] The Ficalibacterium according to the above [9], wherein the daily intake effective for promoting the production of the Ficalibacterium is 0.5 to 11.9 g (cocoa-derived luminacoid) How to promote the production of
[11] The method for promoting the production of Ficalibacterium according to any of [8] to [10], wherein the cocoa-derived luminacoid is ingested in the form of a fat / oil processing composition.
[12] A method for treating, preventing or ameliorating a disease or condition that can be treated, prevented or ameliorated by the production of a species of Ficalibacterium, comprising ingesting or administering an effective amount of cocoa-derived luminacoid.
[13] For the production of an agent for promoting the production of Ficalibacterium, for producing a therapeutic, preventive or ameliorating agent for a disease or condition that can be treated, prevented or ameliorated by the production of Ficalibacterium. Cacao, as a production promoter of Ficalibacterium spp., Or as a therapeutic, preventive or remedy for diseases or conditions that can be treated, prevented or ameliorated by the production of Ficalibacterium spp. Use of Luminakoid derived.
[14] A cocoa-derived luminacoid for promoting the production of a ficalibacterium, or treating or preventing or ameliorating a disease or condition that can be treated, prevented or ameliorated by the production of a ficalibacterium.

  Since the composition and the preparation of the present invention utilize ingredients contained in cocoa which has been used as a raw material of food for many years, the composition and the preparation of the present invention can be taken over a long period of time It is advantageous in that the side effects are small and the safety is high.

It is the figure which showed transition of the frequency | count of defecation in Experiment 1 about the test food group and the control food group. It is the figure which showed transition of the stool color in Experiment 1 about the test food group and the control food group. It is a figure showing change of occupancy of total number of enteric flora of Enteric flora of the genus Ficaribacterium bacteria after intake for Test Example 1 in Test Example 1 for test food group and control food group. It is the figure which showed the dried feces weight of the 11-13th day after the test start in Experiment 2 about a test feed group and a control feed group. It is the figure which showed the cecal contents weight at the time of autopsy in Experiment 2 about a test feed group and a control feed group. It is the figure which showed the cecal short-chain fatty acid amount (butyric acid) in Experiment 2 about a test feed group and a control feed group. It is the figure which showed the cecal short-chain fatty acid amount (propionic acid) in test example 2 about a test feed group and a control feed group. It is the figure which showed the cecal short-chain fatty acid amount (acetic acid) in Experiment 2 about a test feed group and a control feed group.

Detailed Description of the Invention

  In the present invention, "cocoa-derived luminacoid" means a luminacoid contained in cacao, and typically, it is a cocoa bean-derived luminacoid. Therefore, in the present invention, cocoa luminacoids extracted (including crude extraction) or purified (including crude purification) from cocoa plants or their processed products can be used as the active ingredient of the present invention.

  Here, "luminacoid" is a generic name for all food components that reach the large intestine without being digested and absorbed in the small intestine, and is classified into non-starch luminacoid and starch-based luminacoid. Non-starch luminacoids are classified as resistant proteins (Resistant Protein, RP), dietary fiber, oligosaccharides, sugar alcohols and others. Dietary fiber is further classified into lignin and polysaccharides. The polysaccharides include vegetable polysaccharides, animal polysaccharides, microbial polysaccharides and chemically modifying polysaccharides. Starch luminacoids include resistant starch and resistant dextrin. Cocoa-derived luminacoids include resistant proteins and dietary fibers.

  In the present invention, cacao plants which can be a raw material of cacao-derived luminacoids or their processed products include cacao bark, cacao leaves, cacao beans, cacao shells, cacao mass, defatted cacao mass, cocoa powder etc., various parts of plants or cacao A processed bean product can be mentioned. Cocoa mass is obtained by grinding cocoa beans, and defatted cocoa mass can be obtained by removing fats and oils from cocoa mass. The removal method in particular of fats and oils is not restricted, and it can carry out according to publicly known methods, such as expression. If defatted cocoa mass is crushed, it becomes cocoa powder. When extraction is carried out using a cacao plant or a processed product thereof as a raw material, it is preferable to use cacao mass or cocoa powder which has been subjected to an atomization treatment such as grinding or pulverization from the viewpoint of extraction efficiency. In addition, the plant body of cacao can also contain things other than the plant body of cacao without intention or intention. In addition, when extraction is carried out using a cacao plant or its processed product as a raw material, it is possible to unintentionally or unintentionally include substances other than cacao plants. In addition, cacao mass and cocoa powder may also contain unintentional and unintended objects other than cacao plants.

  The extraction method which uses the plant body of cocoa or its processed product as a raw material is known, For example, according to the description of Unexamined-Japanese-Patent No. 2009-183229 or 2011-93807, preparing a cacao-derived luminacoid-containing composition it can. The extraction solvent is not particularly limited, but it is preferable to use water or an alkaline aqueous solution. In addition, purification methods using cocoa plants or their processed products as raw materials may be known methods such as synthetic adsorbent, ion exchange resin, ultrafiltration, activated clay treatment, etc., and are particularly limited. is not.

  In the present invention, the cocoa-derived luminacoid content is determined by the indigestible protein content and the dietary fiber content. The indigestible protein content can be quantified by the Kjeldahl method (the official method of protein determination) after extraction by the method for extracting indigestible proteins described in the examples. In addition, by performing the artificial digestion test described in the Examples, it can be confirmed that the protein is a nondigestible protein. In addition, the dietary fiber content can be quantified by the enzyme-weight method (the official method by AOAC International AOAC International, AOAC Method 985.29, aka: Proski method).

  Since the cocoa-derived luminacoids can be prepared from cocoa plants, the composition and preparation of the present invention may contain components derived from cocoa beans other than cocoa-derived luminacoids. Such components include polyphenols, theobromine, caffeine, amino acids, peptides, fatty acids and the like. In addition, the composition and preparation of the present invention may contain ingredients not derived from cocoa.

  The composition and preparation of the present invention can be provided solely by cocoa-derived luminacoids, or can be provided by mixing cocoa-derived luminacoids with other components. The blending amount of the cocoa-derived luminacoid in the composition and the preparation of the present invention can be arbitrarily determined according to the purpose, use, form, dosage form, symptoms, body weight and the like, and the present invention is not limited thereto. For example, the content of cocoa-derived luminacoid in the composition and preparation of the present invention can be 2% or more in dry mass ratio in solid content, preferably 2 to 90% by mass, more preferably 2 to 50. It can be made into mass%, more preferably 5 to 35 mass%, further preferably 10 to 21 mass%. In the present invention, the preparation of the present invention may be composed of cocoa-derived luminacoid, and the composition of the present invention may be composed of cocoa-derived luminacoid and other components.

  As shown in the Examples below, the cacao-derived luminacoid has an action to promote intestinal flora improvement, specifically, an action to promote the production of Ficalibacterium bacteria. Therefore, the cacao-derived luminacoid (in particular, cacao bean-derived luminacoid) can be used as an intestinal flora improvement promoter and a Ficaribacterium bacteria production promoter, and a method for promoting intestinal flora improvement and a calico It can be used in a method for promoting the production of a bacterium belonging to the genus Bacillus. In addition, cocoa-derived luminacoids (in particular, cocoa bean-derived luminacoids) can also be used as a composition for promoting the improvement of intestinal flora and a composition for promoting the production of Ficalibacterium bacteria.

  Here, "promoting the production of Ficalibacterium bacteria" means promoting the expression and growth of Ficalibacillus bacteria, and the degree of promotion of the production of Ficalibacillus bacteria is The occupancy rate of bacteria can be evaluated as an index (see Examples). Specifically, the ratio of Ficalibacterium to enterobacteria after ingestion or administration of cacao-derived luminacoid (in particular, cacao bean-derived luminacoid) is determined by the ratio of Ficusibacteria belonging to the intestinal flora before ingestion or administration. When it is greater than bacteria, it is preferably about 1.1 times or more, more preferably about 1.2 times or more, still more preferably about 1.3 times or more, still more preferably When it is 1.4 times or more, particularly preferably 1.5 times or more, still more preferably 1.6 times or more, still more preferably 1.8 times or more, most preferably 2 times or more. It can be determined that the production of genus bacteria has been promoted.

  The method of the present invention for promoting the production of Ficalibacterium can be carried out by feeding or administering an effective amount of cocoa-derived luminacoid to human or non-human animals.

  The use of cocoa-derived luminacoids in the present invention may be in human and non-human animals and samples derived therefrom, and both therapeutic and non-therapeutic uses are contemplated. Here, "non-therapeutic" means that the act of surgery, treatment or diagnosis of a human being (ie, medical act on a human) is not included, and specifically, a doctor or a person who has been instructed by a doctor Means not include methods of performing surgery, treatment or diagnosis on humans.

  In the present invention, the cacao-derived luminacoid can be used for the treatment, prevention or amelioration of diseases and conditions in which promotion of the production of Ficalibacterium is effective for the treatment, prevention or amelioration.

  Diseases and conditions that can be treated, prevented or ameliorated by promotion of production of the genus Ficalibacterium include inflammatory diseases (eg, inflammatory bowel diseases such as ulcerative colitis and Crohn's disease), allergic diseases (eg, Food allergy, hay fever, asthma, allergic rhinitis, drug allergy, atopic dermatitis, mite allergy) and diseases thought to be caused by intestinal bacterial symbiosis balance (Dysbiosis) (eg, Crohn's disease, colon cancer, inflammation) Bowel Disease, Irritable Bowel Syndrome, Intestinal Bacterial Hyperplasia (SIBO), Pseudomembranous Colitis (Clostridium difficile enteritis), Antimicrobial agent-induced diarrhea, alcoholic steatohepatitis (ASH) or nonalcoholic steatohepatitis Liver diseases such as (NASH), obesity, type 2 diabetes, allergic diseases, psychiatric diseases such as autism, and multiple sclerosis). As shown in the examples below, the cocoa bean-derived luminacoid can promote the production of Ficalibacterium, and the increase in Fikaribacterium thus far leads to an anti-inflammatory and anti-allergic action. In addition, it has been shown that a decrease in Ficalibacterium is associated with a disease (such as Crohn's disease) that is considered to be caused by dystrophy of intestinal bacteria (Dysbiosis) (Non-patent Documents 2 and 3 and Proc. Natl. Acad. Sci. USA. 2013, 105 (43): 16731-16736). Therefore, the cacao-derived luminacoid is a composition or therapeutic agent for the treatment, prevention or improvement of inflammatory diseases, allergic diseases and diseases (such as Crohn's disease) considered to be caused by intestinal bacterial symbiotic imbalance (Dysbiosis), It can be used as a preventive or ameliorating agent, and also used in a method of treating, preventing and ameliorating a disease (such as Crohn's disease) that is considered to be caused by inflammatory disease, allergic disease and intestinal bacterial symbiotic imbalance (Dysbiosis) be able to.

  The composition and the agent of the present invention, the therapeutic agent, the preventive agent and the remedy of the present invention, and the therapeutic, preventive and ameliorating composition of the present invention are in the form of pharmaceuticals, quasi drugs, food and drink, feed and the like. Can be provided according to the description below. In addition, the method of the present invention for promoting the production of the genus Ficalibacterium and the method of the present invention for treating, preventing and improving can be carried out according to the following description. When the therapeutic, prophylactic and ameliorating compositions of the present invention are intended for pharmaceutical use, they can be a therapeutic pharmaceutical composition, a prophylactic pharmaceutical composition and a pharmaceutical composition for amelioration.

  In the case of administering or ingesting a cocoa-derived luminacoid, which is an active ingredient of the present invention, to humans and non-human animals, a composition having an increased content of luminacoid derived from cocoa beans can be used, and such a composition Since it contains almost no fat derived from cacao beans and has almost no bitter and astringent taste, it is useful as a material for various food and drink products, medicines, quasi-drugs, feeds, chemical products and the like.

  The cocoa-derived luminacoid which is an active ingredient of the present invention can be orally administered to human and non-human animals. Oral agents include granules, powders, tablets (including sugar-coated tablets), pills, capsules, syrups, emulsions, suspensions. These preparations can be formulated using a pharmaceutically acceptable carrier according to a method commonly used in the art. Pharmaceutically acceptable carriers include excipients, binders, diluents, additives, flavors, buffers, thickeners, colorants, stabilizers, emulsifiers, dispersants, suspending agents, preservatives, etc. Can be mentioned.

  The cocoa-derived luminacoid, which is an active ingredient of the present invention, is also administered to human and non-human animals by intravaginal administration, intranasal administration, instillation, suppository, etc. in the body other than oral administration. It is possible according to. For example, by setting a viscous liquid composition containing cocoa-derived luminacoid or a semi-solid composition containing cocoa-derived luminacoid, the function of chewing and swallowing is reduced, and human beings can not take orally or orally. And can also be administered to non-human animals. Even if the function of chewing and swallowing is deteriorated due to aging or the like by taking or administering the composition and the preparation of the present invention other than oral intake, it can be expected to promote the production of the genus Ficacalibacterium. The treatment, prevention and amelioration of diseases (eg, Crohn's disease) thought to be caused by inflammatory diseases, allergic diseases, and intestinal bacterial symbiotic imbalance (Dysbiosis) in these human and non-human animals can be expected.

  Cocoa-derived luminacoid, which is an active ingredient of the present invention, can be orally taken by humans and non-human animals. When the cocoa-derived luminacoid is orally ingested, the cocoa-derived luminacoid may be in an isolated, purified or crudely purified form, or in the form of a food or food material containing the cocoa-derived luminacoid. In addition, the cocoa-derived luminacoid can be arbitrarily selected from normal temperature, warm state, cold state and the like when orally ingested by humans and non-human animals.

  When the cocoa-derived luminacoid which is the active ingredient of the present invention is provided as a food, the cacao-derived luminacoid can be contained as it is in a food, and the food is a food containing an effective amount of cacao-derived luminacoid. Here, the phrase "containing an effective amount of cacao-derived luminacoid" refers to a content such that cacao-derived luminacoid is ingested within the range described later when the amount that is usually consumed in individual foods is ingested. Also, "food" refers to health food, functional food, health food (for example, food for specified health use, nutrition food for functional use, food for functional indication), special purpose food (for example, food for infants, food for pregnant women, disease) It is used in the meaning including the food for the elderly. The form of the “food” is not particularly limited, and may be, for example, a form of a beverage, a semi-liquid or gel form, or a solid form.

  Since the cacao-derived luminacoid has an action to promote the production of Ficalibacterium bacteria, it can be provided by being contained in foods taken daily as well as foods taken as supplements. The food provided by the present invention is not particularly limited in its form or shape, but preferably includes foods that use cocoa beans as a main raw material, more preferably a fat-processing composition, and even more preferably Are fats and oils processed foods such as chocolate and cocoa.

  As described above, the concentrated cocoa bean-derived luminacoid composition can be used in the present invention for efficiently ingesting the cocoa bean-derived luminacoid. Therefore, it is preferable that the food and supplement containing cocoa beans as a main ingredient are, for example, those containing a high concentration of lucocoid derived from lucocoa beans, more preferably a fat and oil processing composition containing lumonacoids derived from cocoa beans from high concentrations, More preferable are fat-processed foods (specifically, chocolate and cocoa) containing a high concentration of cocoa bean-derived luminacoid.

  Here, the content of the cocoa bean-derived luminacoid in the food and the supplement is not particularly limited as long as consumption of the cocoa bean-derived luminacoid is possible, but from the viewpoint of efficient intake of the cocoa bean-derived luminacoid The content in the processing composition can be, for example, 2 to 90% by mass, preferably 2 to 50% by mass, more preferably 5 to 35% by mass, and still more preferably 10 based on the solid content of the composition. It is -21 mass%. In addition, the content of cocoa bean-derived luminacoid in foods and supplements is not particularly limited as long as the intake of cacao bean-derived luminacoid is possible, but from the viewpoint of efficient intake of cacao bean-derived luminacoid, oil and fat processing The content in the composition is, for example, preferably 0.5 to 11.9 g, more preferably 1.4 to 8.8 g, still more preferably 2.6 to 5.2 g, per 25 g of solid content of the composition. .

  Here, the content of cocoa bean-derived dietary fiber in foods and supplements is not particularly limited as long as consumption of cocoa bean-derived indigestible protein is possible, but efficient intake of cocoa bean-derived dietary fiber From the point of view, the content in the oil-fat processing composition can be, for example, 1 to 40% by mass, preferably 4 to 28% by mass, more preferably 6 to 20% by mass, based on the solid content of the composition. Still more preferably, it is 8 to 16% by mass. Also, the content of cocoa bean-derived dietary fiber in foods and supplements is not particularly limited as long as consumption of cocoa bean-derived indigestible protein is possible, but the efficient intake of cocoa bean-derived dietary fiber From the viewpoint, the content in the oil-fat processing composition is, for example, preferably 0.3 to 9.4 g, more preferably 1.0 to 7.0 g, and still more preferably 2.0 to 25 g of solid content of the composition. It is 4.0g.

  Here, the content of the cocoa bean-derived indigestible protein in the food and the supplement is not particularly limited as long as consumption of the cocoa bean-derived indigestible protein is possible, but the cocoa bean-derived indigestible protein is not particularly limited. From the viewpoint of efficient intake, the content in the oil and fat processing composition can be, for example, 0.5 to 15% by mass, preferably 1 to 10% by mass, and more preferably, per solid content of the composition. It is 1.5 to 8% by mass, still more preferably 2 to 5% by mass. In addition, the content of cocoa bean-derived indigestible protein in foods and supplements is not particularly limited as long as consumption of cocoa bean-derived indigestible protein is possible, but the efficiency of cocoa bean-derived indigestible protein From the viewpoint of dietary intake, the content in the oil-fat processing composition is, for example, preferably 0.2 to 2.5 g, more preferably 0.4 to 1.8 g, and still more preferably 25 g solid content of the composition. It is 0.6 to 1.2 g.

  The food provided by the present invention is not particularly limited as long as it is a food that can contain cocoa-derived luminacoid as well as a food that mainly contains cocoa beans, such as chocolate and cocoa. For example, starch-based foods such as breads, biscuits, noodles, crackers, feeding bars; various confectioneries such as candies, gums, gummi, snacks; milk, processed milk, ice cream, fermented milk (yoghurt etc. ), Milk and dairy products such as milk drinks, cheeses, butters and creams; Desserts such as puddings, jellies, bavarois and mousses; Beverages such as non-alcoholic beverages and alcoholic beverages; Meat and meat processing such as hams and sausages Products: processed fish meat products such as kamaboko, bamboo rings, fish meat sausages; processed fruit products such as jams and purees; seasonings such as roux and sauces. The cocoa bean-derived luminacoid can be appropriately blended at the stage of an appropriate production process depending on the properties of the respective food and purpose.

  The medicines and foods of the present invention utilize ingredients contained in cocoa which has been heavily used as foods, and therefore mammals (eg, humans, mice, rats, rabbits, dogs, cats, cattle, etc.) which need them. , Horses, pigs, monkeys, etc.). The dose or intake of cocoa-derived luminacoids (in particular, cocoa bean-derived luminacoids) can be determined depending on the sex, age and body weight of the recipient, symptoms, time of administration, dosage form, route of administration, drugs to be combined, etc. For example, when orally administering cacao-derived luminacoid (in particular, cacao bean-derived luminacoid) as a pharmaceutical, 0.5 to 11.9 g, preferably 1.4 to 8.8 g, more preferably 2.6 to 1 day per adult It can be administered in the range of 5.2 g. When a cocoa-derived luminacoid (in particular, cocoa bean-derived luminacoid) is taken as a food, it is preferably 0.5 to 11.9 g, preferably 1.4 to 8.8 g, more preferably 2.6 per adult per day. It can be administered in a range of ̃5.2 g.

  The compositions and preparations of the present invention are not limited in combination with other orally ingestible compositions. For example, it can be used in combination with a material or composition that can be expected to have an effect of preventing, treating or ameliorating a disease (such as Crohn's disease) that is considered to be caused by anti-inflammatory and anti-allergic actions and intestinal bacterial symbiotic balance imbalance (Dysbiosis) It is possible to further enhance the production promoting effect of Kalibacterium bacteria.

  The composition and use according to the present invention can be provided as a composition comprising a daily intake of cocoa-derived luminacoid effective to promote the production of the genus Ficaribacterium. In this case, the composition and the preparation of the present invention may be packaged so as to be able to take an effective intake for one day, and the package form is one package as long as an effective intake for one day can be taken Even if there are, it may be a plurality of packages. When provided in the form of a package, it is desirable that the description of the intake be provided on the package so that an effective intake for one day can be taken, or a document with the description is provided together. Moreover, when providing the effective intake amount for 1 day with multiple packages, the package of the effective intake amount for 1 day can also be provided by a set for convenience of intake.

  The package form for providing the composition and the preparation of the present invention is not particularly limited as long as it is a form that defines a fixed amount, and, for example, wrapping paper, bag, soft bag, paper container, can, bottle, capsule, etc. The container etc. which can be accommodated are mentioned.

  The composition and preparation of the present invention are preferably administered or ingested continuously for 1 week or more, and the administration and intake period is more preferably 1 to 2 weeks, particularly preferably, in order to exert their effects better. 1 to 4 weeks. Here, "continuously" means continuing administration or intake daily. When the composition and the preparation of the present invention are provided in the form of a package, an effective intake for a fixed period (for example, one week) may be provided as a set for continuous intake.

  According to another aspect of the present invention, there is provided a method of promoting intestinal flora improvement and a method of promoting Ficusalobacterium, which comprises ingesting or administering an effective amount of cocoa-derived luminacoid to human or non-human animals. Methods of promoting the production of The promotion method of the present invention can be carried out according to the description of the composition and preparation of the present invention.

  According to still another aspect of the present invention, treatment or prevention is achieved by promoting the production of a species of Ficalibacterium bacteria, which comprises ingesting or administering an effective amount of cocoa-derived luminacoid to human or non-human animals. There is provided a method for treating, preventing or ameliorating a disease or condition that can be ameliorated or improved. The treatment, prevention or amelioration method of the present invention can be practiced according to the description of the composition and agent of the present invention.

  According to still another aspect of the present invention, there is provided a use of a cocoa-derived luminacoid for the preparation of an intestinal flora improvement promoter or a Ficaribacterium production enhancer, and an intestinal flora improvement promoter. Alternatively, there is provided the use of a cocoa-derived luminacoid as a production promoter of Ficalibacterium. According to the present invention, there is also provided the use of a cocoa-derived luminacoid for the manufacture of an agent for treating, preventing or ameliorating a disease or condition which can be treated, prevented or ameliorated by promoting the production of the genus Ficalibacterium. The use of a cocoa-derived luminacoid as a therapeutic, prophylactic or ameliorating agent for a disease or condition that can be treated, prevented or ameliorated by promoting the production of a Kalibacterium bacteria is provided. The use of the present invention can be carried out according to the description of the composition and preparation of the present invention.

  According to still another aspect of the present invention, there is provided a cacao-derived luminacoid for use in promoting intestinal flora improvement or for use in promoting the production of Ficaribacterium. According to the present invention, there is also provided a cocoa-derived luminacoid for use in the treatment, prevention or amelioration of a disease or condition which can be treated, prevented or ameliorated by promoting the production of a species of Ficalibacterium. The above-mentioned cocoa-derived luminacoids can be practiced according to the description of the composition and preparation of the present invention.

  The present invention will be more specifically described based on the following examples, but the present invention is not limited to these examples.

Test Example 1: Examination of the production promoting effect of Ficaribacterium bacteria by cacao bean-derived luminacoid (1)
The following tests were conducted to verify the influence of the cocoa bean-derived luminacoid on the production of the genus Ficaribacterium.

  The subjects were 40 healthy Japanese women aged 20 to 50 years old who were screened and screened, and an evaluator blinded parallel group comparison test was conducted. The results were obtained for 16 in the test food group and 15 in the control food group, except for 9 people who discontinued the test on the way. During the study, food restrictions and other restrictions (details of food restrictions and other restrictions are given below) were performed.

  Screening 7 days before intake start (day -7, -1W), lifestyle questionnaire (age, medical history, complications, presence or absence of food allergy, intake status of medicines and health food, confirmation of drinking etc.), awareness Questionnaire (investigation of symptoms related to intestinal adjustment), physical examination (height, weight, blood pressure, pulse rate, BMI), defecation status (number of stools, feces, stool volume), age, eating habits (cacao) Products, natto, dairy products, etc.) We have met the exclusion criteria for daily use (the details of the exclusion criteria are shown below) and selected 40 people with an average stool frequency of 4 times or less weekly.

Those who were below the exclusion criteria for screening were excluded from screening.
-Currently having some chronic disease and receiving drug treatment-Person who is allergic to chocolate, milk and soy-Person who has lactose intolerance-Cocoa products 4 times a week for 3 months before screening Those who have consumed more than 3 weeks before screening, those who have been taking natto four times a week or more, and during 3 months before screening, those who consume lactobacillus containing food such as yogurt, lactobacillus drink, intestinal juice agent more than 4 times a week Those who are taking / consuming medications, quasi-drugs, supplements, health food, food for specified health use (Tokuho) which may affect the results of this test on a daily basis, or during the test・ Persons who intend to take in ・ Persons who participated in other clinical trials and monitor trials within one month before screening, or those who are planning to participate in other clinical trials after consenting to this clinical trial Those who are pregnant, plan of pregnancy during the study period, those alcohol multi-drinking party in the hope that a person or breastfeeding (in pure alcohol terms, drinkers of more than more than one day average 60g)
・ Others who are judged inappropriate as subjects

Dietary restriction and other restricted subjects during the study were instructed to have a normal life during the study and to comply with the following restrictions.
Matters related to meals, drinks and specialties, and meals do not significantly change the diets (meal amount and content of meals) so far, and excessive dieting and overeating that largely deviate from the daily range are avoided. However, the intake of natto is prohibited from screening until the completion of stool collection two weeks after intake.
・ The intake of drinks does not limit the amount and frequency of intake, such as green tea and coffee, but we do not largely change the degree (amount, type, etc.) of previous intake.
・ Snacks should be free in principle, but should not exceed the amount usually consumed. However, the intake of food and drink containing cacao other than the test food is prohibited from screening to collection of stool two weeks after intake is completed.
・ Alcohol intake is not limited in principle, but we do not largely change the level (amount, type, etc.) of alcohol intake so far.
・ Pharmaceuticals (including over-the-counter drugs), quasi-drugs, supplements, food for specified health use or health food that may affect this study will stop collecting stool two weeks after intake from the time of screening. Prohibit use or intake. Chinese medicine prescription including antibiotics, laxatives, constipation medicines, intestinal conditioners, constipation and aphrodisiacs that have the effect of improving diarrhea and indigestion, jaundice, large yellow rice, largepox, cinnamon, ginseng etc. Yu-Tang, Go-San, HanSan-Shin-Tang, Kamiso-San-Hang-Shu, Daejeo-Shu-Tang, Jing-San-Tang, Tao-Feng-Sen-Tang, Bofu-Tshou-San) and herbal medicines Drugs (including over-the-counter drugs), quasi-drugs, supplements, food for specified health use (Tokuho), or health food, which contains chewing etc., falls under this category.
・ Record daily life diary during the examination period.
• From the time of screening until the end of the stool collection 2 weeks after intake, major life changes are avoided as much as possible.

  The test food is a continuous cocoa bean-derived luminacoid high content oil processing composition ("chocolate effect cocoa 72%" Meiji Co., Ltd.) 25 g (5 sheets of oil processing composition per sheet) each day for two weeks I had it ingested. Since the above-mentioned fat processing composition contains 127 mg (total polyphenol amount) of cocoa polyphenols per sheet, the cocoa polyphenol consumed by the subject per day is 635 mg. In addition, since the above-mentioned oil processing composition contains 0.6 g of dietary fiber and 0.18 g of indigestible protein per sheet, the amount of dietary fiber consumed by a subject per day is 3.0 g, which is indigestible The amount of protein is 0.88 g. That is, the amount of lucocoid derived from cocoa beans consumed by the subject per day is 3.88 g. As a control food, commercially available chocolate ("White Chocolate", Meiji, Ltd.) was continuously taken every 25 g (6 sheets of 4.2 g of oil-processed composition) daily for two weeks. The control food is free of polyphenols, dietary fiber and resistant proteins.

  Moreover, in the test food, the content of 1 to 4 mer polyphenols to be ingested per day was 76 mg. Breakdown of main components: 10.4 mg of catechin (monomer), 27.8 mg of epicatechin (monomer), 15.8 mg of procyanidin B2 (dimer), procyanidin B5 (dimer) It was 4.4 mg, procyanidin C1 (trimer) 9.6 mg, and cinnamtanin A2 (tetramer) 7.1 mg. In addition, about each component, it measured using HPLC. As a column, Deverosil-ODS-HG5 (4.6 mm × 250 mm, φ5 μ, manufactured by Nomura Chemical Co., Ltd.) was used. The eluent consisted of solution A and solution B. Solution A used a 0.1% aqueous solution of trifluoroacetic acid, and solution B used a solution of 0.1% trifluoroacetic acid / acetonitrile. The flow rate of the eluent through the column is 0.8 ml / min, and the condition of the gradient is that the proportion of solution B in the whole eluent is 10% at the start point, 10% at 5 minutes and 10% at 35 minutes after the start 25%, 100% after 40 minutes starting, and 100% after 45 minutes starting. The amount of sample injection was 10 μL, and each component was quantified by epicatechin equivalent using epicatechin as a standard. Moreover, polyphenol content was measured by Prussian blue method. Specifically, polyphenol content was calculated using commercially available epicatechin as a standard substance according to the method described in Martin L. Price and Larry G. Butler, J. Agric Food Chem. 1977, 25 (6): 1268-1273. .

  Moreover, in the test food, the content of dietary fiber consumed per day was 3.0 g. Specifically, it was calculated by the enzyme-weight method which is (the official method of AOACS International AOAC International).

  In addition, the content of indigestible protein to be ingested in one day in the test food was 0.88 g. Specifically, the amount of protein extracted according to the following extraction method of indigestible protein was calculated by the Kjeldahl method (the official method of protein determination). In addition, it was confirmed by the following artificial digestion test that the extracted protein was a nondigestible protein.

Extraction Method of Indigestible Protein The chocolate was dissolved in hot water, and 5 times the amount of hexane of chocolate was added and stirred for 3 hours. The precipitate was collected by centrifugation at 10,000 rpm for 10 minutes at 4 ° C. The collected precipitate was suspended in hexane three times the amount of the initial chocolate and stirred for 1 hour. The mixture was centrifuged at 10,000 rpm for 10 minutes at 4 ° C., and the precipitate was air-dried overnight (referred to as chocolate powder). The aforementioned chocolate powder was suspended in 20 volumes of deionized water and stirred for about 10 minutes. The pH was checked and adjusted to pH 12 with NaOH. After stirring again for 10 minutes, the pH was confirmed and adjusted to pH 12 with NaOH. The temperature was raised to 50 ° C., and when it reached, the pH was confirmed and adjusted to pH 12 with NaOH. The temperature was raised to 70 ° C., and when it reached it was extracted for 30 minutes. The supernatant was collected by centrifugation at 10,000 rpm for 10 minutes at room temperature. Phosphoric acid was added to the obtained supernatant to adjust the pH to 2.0, and the mixture was allowed to stand overnight at 4 ° C. The precipitate was collected by centrifugation at 10,000 rpm for 10 minutes at room temperature. The precipitate was suspended by adding 5 times the amount of the raw material (choco powder weight) to deionized water, suspended, and centrifuged at 10,000 rpm for 10 minutes at 25 ° C. to remove the supernatant. The washing was carried out twice. The precipitate was collected and dried under vacuum at 80 ° C. for 72 hours.

Artificial digestion test (1) pepsin digestion After adding water to the test sample to make it 10%, the pH was adjusted to 2.0 with hydrochloric acid. Pepsin (163-00642, Wako Pure Chemical Industries, Ltd.) was added thereto 1/100 of the amount collected and reacted at 37 ° C. for 4 hours.

(2) Pancreatin digestion The reaction product of (1) above was adjusted to pH 8-10 with sodium hydroxide, and pancreatin (163-00142, Wako Pure Chemical Industries, Ltd.) was added at 1/50 of the collected amount. The reaction was allowed to proceed at 37.degree. C. for 16 hours. After completion of the enzyme reaction, the enzyme reaction was stopped by heating at 100 ° C. for 5 minutes. Further, in both (1) and (2), water was added in an amount (weight) equivalent to the amount of enzyme added instead of the enzyme, and a blank area operated in the same manner as the enzyme treatment was treated simultaneously with the sample.

(3) Recovery of undigested substance (residue) The reaction product of (2) above was adjusted to pH 2.0 with hydrochloric acid, centrifuged at 10,000 rpm for 10 minutes at 4 ° C., and the precipitate was recovered. To the collected precipitate, 5 times the amount of sampled water was added to dissolve and wash the precipitate, and centrifugation (10,000 rpm, 10 minutes, 4 ° C.) was performed again. This operation was performed twice in total.

(4) Drying The collected precipitate was lyophilized. At that time, the weight before and after lyophilization (hereinafter referred to as the amount of recovered residue) was measured. The amounts of components were determined by the Kjeldahl method.
The digestibility was calculated by the following formula.

  As a result, the digestibility of protein in the indigestible protein-containing product was 20%, and that of casein tested at the same time was 99.3%.

  From the above, it can be confirmed that the protein extracted from chocolate is indigestible.

Evaluation and results The intake start day is the first day, and from 7 days before the intake start (day -7, -1W) to the last day of intake (day 14, 14W), daily life diary (confirmation of test food intake, awareness Symptoms were recorded, and defecation status (the number of stools, feces, stool volume), sex cycle, drug intake status, etc. recorded 7 days before the intake start day. 7 days prior to intake (day -7, -1W) and last day of intake (day 14, 14W), lifestyle questionnaire, awareness questionnaire, physical examination (height, weight, blood pressure, pulse rate, BMI) collection Carried out. In addition, analysis of fecal flora (T-RFLP analysis of fecal flora by the Nagashima method), quantification of the number of bifidobacteria in feces and the total number of bacteria, measurement of occupancy rate of bifidobacteria (real-time PCR method), comprehensive coverage of feces Flora analysis (DGGE method, next-generation amplicon sequencing method: evaluation of the subject intestinal flora (genus level) by metagenomic analysis was performed. The obtained data are shown as mean value ± standard error. Comparison between groups such as stool color and stool volume: “t-test for independent samples” (Analysis software: “IBM SPSS Statistics 23”) Comparison between number of stools: “Mann-Whitney U test” (Analysis software: "IBM SPSS Statistics 23") Comparison between groups of comprehensive bacterial flora analysis: Comparison between control food group and test food group was evaluated by t-test using Excel statistics (SSRI) (Level of significance is indicated Less than 5%).

  The frequency of defecation shows a marked increase with time in the test food group, and the day 0 to day 7 (0W to 1W), 8 against day -7 to day 1 (-1W to 0W) There was a significant difference (risk rate (p value) less than 5%) for both days 14 to 14 (1 W to 2 W). A clear increase in defecation frequency was observed in the test food group compared to the control food group (FIG. 1).

  Fecal properties were evaluated by stool color and defecation volume. The stool color was evaluated by a 5-step stool color score. Specifically, the stool color score value is 1: yellow to yellowish brown 2: brown to 4: dark brown to 5: dark brown to black (Intestinal Bacteriology Journal. 2004, 18 (2) 107-115), the test subjects are marked with the above-mentioned 5 levels of stool color score value and name, and the corresponding stool color passes the color printed stool color scale for visual comparison. The subject was allowed to observe the color himself. As a result, the stool color score value 14 days after ingestion of the test food group showed a value significantly lower than the stool color score value of the control food group (FIG. 2). That is, in the fecal color, the test food intake group showed a tendency to improve after 14 days of intake, but the control food intake group showed almost no change (FIG. 2). For stool volume, days 0 to 7 (0 W to 1 W), or days 8 to 1 week prior to intake (-1 W to 0 W) on the whole stool volume before (-1 W to 0 W) The ratio of the total amount of stools for each week from the 14th day (1 W to 2 W) was determined. As a result, the stool volume of the test food group tended to increase with time (data not shown).

  From the results of FIG. 1 and FIG. 2, it is confirmed that the number of stools and the amount of stools increase and the stool color is improved by the consumption of the cocoa bean-derived luminacoid.

  In addition, metagenomic analysis using the next-generation amplicon sequencing method (see Proc Natl Acad Sci USA 2011 (108) (Suppl 1): 4516-4522) was performed using the MiSeq system (manufactured by Illumina). Classification of each bacterium constituting the flora was performed according to 16S rDNA sequence information (see Nucl Acids Res. 2007, 35:18. E120). As a result, in the test subject intestinal flora (genus level), the occupancy rate of the Ficalibacterium bacteria when the total number of bacteria in the intestinal flora is 100% is before intake (0 day in the test food intake group) It significantly increased after ingestion (day 14) compared to the eye (Figure 3). That is, it was confirmed that the increase in the number of stools, the increase in the amount of stools, and the improvement in stool color were due to the increase in the genus Ficalibacterium.

  From the above results, it was confirmed that cacao bean-derived luminacoid promotes the production of a ficalibacterium. Therefore, cacao bean-derived luminacoids are improved by promoting the production of Ficalibacterium such as inflammatory diseases, allergic diseases, and diseases (eg, Crohn's disease) that are considered to be caused by intestinal bacterial symbiotic imbalance (Dysbiosis). It has been shown to have an improvement effect on diseases and medical conditions.

Test Example 2: Examination of the production promoting effect of Ficaribacterium by Luminousoid derived from cocoa beans (2)
In order to verify the influence that the cocoa bean-derived luminacoid exerts on the production of the ficalibacterium bacteria, the following test was performed using the luminacoid extracted from chocolate.

(1) Preparation of Luminacoid Dissolve 1603 g of a commercial cocoa bean-derived high luminacoid-containing fat and oil processing composition ("Chocolate effect cacao 72%" Meiji Co., Ltd. Meiji) with hot water and add 5 times the amount of hexane (8 L) of chocolate, It degreased by stirring for 3 hours. After centrifugation (10000 rpm, 10 minutes, 4 ° C.), the supernatant was removed and the precipitate was recovered. After adding 3 times the amount of hexane (4.8 L) to the precipitate, it was stirred for 1 hour. After centrifugation, the supernatant was removed and the precipitate was collected and dried overnight in a fume hood. The dried precipitate was pulverized with a mill to obtain 981 g of chocolate powder.

  The chocolate powder (981 g) obtained as described above is suspended in 20 volumes of water (19.6 L), adjusted to pH 12.0 with 8 N NaOH, heated to 70 ° C., and extracted for 30 minutes. The After centrifugation (10000 rpm, 10 minutes, 25 ° C.), the supernatant was recovered.

  The collected supernatant was adjusted to pH 2.0 with phosphoric acid and allowed to stand overnight at 4 ° C. After centrifugation (10000 rpm, 10 minutes, 25 ° C.), the supernatant was removed and the precipitate was recovered.

  To the precipitate, 5 volumes of water (4.9 L) of chocolate powder was added to perform washing with water, and after centrifugation (10000 rpm, 10 minutes, 25 ° C.), the supernatant was discarded. The precipitate obtained by repeating the water washing twice was dried at 80 ° C. for 6 hours in a vacuum drier to obtain 129 g of a cocoa protein-containing substance (protein: 46.6%, dietary fiber: 43.3%) . Since the protein and dietary fiber contained in the obtained cocoa protein-containing substance are resistant to digestion, the cocoa protein-containing substance corresponds to the cocoa bean-derived luminacoid.

(2) Test method In the test, a test feed group ingesting a feed (test feed) containing the cocoa bean-derived luminacoid (cocoa protein-containing material) prepared in (1) above, and a feed not containing the cocoa bean-derived luminacoid ( The control feed was performed on two groups of the control feed group receiving the control feed. As a test feed, a feed in which the 5% cellulose content of AIN93G was replaced with a 5% cocoa protein-containing content was used. As a control feed, a feed in which 5% cellulose, which is insoluble dietary fiber in AIN 93 G, was replaced with 5% corn starch was used. The feed produced by removing cellulose from AIN 93G was produced by Oriental Yeast Co., Ltd.

  After 12 rats of BALB / cA mice (female, 6 weeks old, CLEA Japan, Inc.) were preliminarily bred with a control diet for 1 week, they were divided into groups so that the average body weights would be equal. Grouping was made to be 6 animals in each group.

  Each feed and water was free intake from the start of the study. Body weight and food intake measurements were taken twice a week. In addition, feces for 2 days on the 11th to 13th days after the start of the test were collected, and after freeze-drying, the dry weight was measured.

On the 14th day after the start of the test, whole blood was collected from the abdominal descending vena cava under isoflurane anesthesia. The cecal contents were collected, weighed and stored at -80 ° C. Moreover, the measurement of the cecal short chain fatty acid concentration was performed on the following measuring devices and conditions.
Measuring instrument: Shimadzu organic acid analysis system Column: Shim-Pack SCR-102 (H), 300 mm x 8 mm ID, 2 columns used in series Guard column: Shim-Pack SCR- 102 (H), 50 mm x 6 mm ID
Eluent: 5 mmol / L p-toluenesulfonic acid reaction solution: 5 mmol / L p-toluenesulfonic acid, 100 μmol / L EDTA, 20 mmol / L Bis-Tris
Flow rate: 0.8 mL / min Oven temperature: 45 ° C.
Detector: Conductivity detector CDD-10A
References: Advances in Microbiology. 2015, 5 (7): 531-540 and Benef Microbes. 2016 Jun, 7 (3): 337-344

  The data obtained are shown as mean ± standard error. Statistical analysis used Excel statistics (SSRI), and the comparison of the control feed group and the test feed group was evaluated by t-test. The significance level was less than 5%. There were no significant differences between the groups in the body weight and the total food consumption at the start and end of the test (data not shown).

(3) Results The weight of dried feces 11 to 13 days after the start of the test is shown in FIG. 4, and the weight of cecal contents at dissection is shown in FIG. Also, the amount of short-chain fatty acids (butyric acid, propionic acid, acetic acid) in the cecum is shown in FIG. 6A, FIG. 6B and FIG. 6C.

  As shown in FIG. 4, a significant increase in fecal weight was observed in the test feed group as compared to the control feed group. This result shows that the active ingredient of the stool improvement effect by ingestion of "chocolate effect cocoa 72%" in Test Example 1 is a cocoa protein-containing substance (luminacoid).

  Also, as shown in FIG. 5, a significant increase in cecal content weight was observed in the test feed group as compared to the control feed group. Furthermore, as shown in FIGS. 6A, 6B and 6C, a significant increase in the amount of short-chain fatty acids in the cecum was observed in the test feed group as compared to the control feed group. From these results, it was shown that the cocoa protein-containing substance (luminacoid) has an effect of increasing the amount of feces due to the production of short-chain fatty acids in the cecum, in addition to the increase of feces due to the bulking effect of feces. The short-chain fatty acids in the cecum are produced by Ficalibacterium spp. And are strongly positive between the change in occupancy rate of Ficalibacterium spp. And the change in short-chain fatty acid concentration in human feces. From the fact that a correlation is observed (for example, see Brit J Nutr. 2010, 104 (5): 693-700), in combination with the results of Test Example 1, the cocoa protein-containing substance (luminacoid) is Have been shown to have the effect of promoting the improvement of intestinal flora.

Test Example 3: Examination of the production promoting effect of Ficaribacterium bacteria by cacao bean-derived luminacoid (3)
The following tests were conducted to examine the influence of cocoa bean-derived luminacoid on the production of short chain fatty acids in feces.

  The subjects were selected by screening from healthy Japanese women aged 20 to 50 years old, and evaluator blinded parallel group comparison tests were conducted (test food group, control food group, 30 people each). Food and other restrictions were performed during the study. The same criteria as those described in Test Example 1 were adopted for food restriction and other restrictions during the test period, as well as matters relating to food, drinks and luxury items.

  Screening 7 days before intake start (day -7, -1W), lifestyle questionnaire (age, medical history, complications, presence or absence of food allergy, intake status of medicines and health food, confirmation of drinking etc.), awareness Questionnaire (investigation of symptoms related to intestinal adjustment), physical examination (height, weight, blood pressure, pulse rate, BMI), defecation status (number of stools, feces, stool volume), age, eating habits (cacao) The average number of stools per week was 60, which met an average of 4 times per week, and met the prescribed exclusion criteria for products, natto, foods containing lactic acid bacteria, etc.). The exclusion criteria for screening adopted the same criteria as those described in Test Example 1.

  As the test food and the control food, those prepared and evaluated in the same procedure as described in Test Example 1 were used.

  The evaluation was as follows. Day 1 of intake start day, 7 days before start of intake (-7th day, -1W), last day of intake (14th day, 2W), daily logbook (confirmation of test food intake, recording of symptoms) , Record of defecation status (the number of stools, feces, stool volume, etc., sex cycle, drug intake status etc.) from 7 days before the intake start day). 7 days prior to intake (day -7, -1W) and last day of intake (day 14, 14W), lifestyle questionnaire, awareness questionnaire, physical examination (height, weight, blood pressure, pulse rate, BMI), collection The flight was carried out.

  In addition, short chain fatty acid concentration in stool was measured. The stool short-chain fatty acid concentration was measured according to the conditions described in Test Example 2 using the measurement device described in Test Example 2. As a result, it was confirmed that the short chain fatty acid concentration in feces increased by ingesting the test food (data not shown). Short-chain fatty acids in the large intestine are produced by Ficalibacterium spp., And are strongly positive between the change in occupancy rate of Ficalibacterium spp. And the change in short-chain fatty acid concentration in human feces. From the fact that a correlation is observed (for example, see Brit J Nutr. 2010, 104 (5): 693-700), in combination with the results of Test Example 1, the cocoa protein-containing substance (luminacoid) is It was shown also in this test example that it has an effect of promoting the production of and improving the intestinal flora.

Claims (14)

  A composition for promoting the production of a genus of Ficalibacterium, comprising cocoa-derived luminacoid.   The composition according to claim 1, comprising a daily amount of cocoa-derived luminacoid effective to promote the production of the genus Ficalibacterium.   The composition according to claim 2, which is packaged for each effective intake for one day.   The composition according to claim 2 or 3, wherein the daily intake effective for promoting the production of Ficalibacterium is 0.5 to 11.9 g (the amount of cocoa-derived luminacoid).   The composition according to any one of claims 1 to 4, wherein the cocoa-derived luminacoid is ingested for one week or more.   The composition according to any one of claims 1 to 5, which is in the form of a fat / oil processing composition.   The composition according to any one of claims 1 to 6, for use in the treatment, prevention or amelioration of a disease or condition that can be treated, prevented or ameliorated by the production of a ficalibacterium.   A method for promoting the production of a genus of Ficalibacterium, comprising ingesting an effective amount of cocoa-derived luminacoid.   9. The method for promoting the production of Ficalibacterium according to claim 8, which comprises taking the cocoa-derived luminacoid at a daily dose effective for promoting the production of the Ficusbacillus bacteria for one week or more. .   The method according to claim 9, wherein the daily intake effective for promoting the production of the ficalibacterium is 0.5 to 11.9 g (cocoa-derived luminacoid). .   The method for promoting the production of the genus Ficaribacterium according to any one of claims 8 to 10, wherein the cocoa-derived luminacoid is ingested in the form of a fat / oil processing composition.   A method for treating, preventing or ameliorating a disease or condition that can be treated, prevented or ameliorated by the production of a genus Ficaribacterium, comprising ingesting or administering an effective amount of cocoa-derived luminacoid.   For the production of an agent for promoting the production of Ficalibacterium bacteria, for the production of an agent for treating, preventing or ameliorating a disease or condition which can be treated, prevented or ameliorated by the production of Fikaribacillus bacteria. A cocoa-derived luminacoid as an agent for promoting the production of Ficalibacterium, or as an agent for treating, preventing or ameliorating a disease or condition that can be treated, prevented or ameliorated by the production of Ficalibacterium. use. A cocoa-derived luminacoid for use in promoting the production of Ficalibacterium, or in treating, preventing or ameliorating a disease or condition that can be treated, prevented or ameliorated by the production of Ficalibacterium.

Images